Japan
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.04 (2.67 - 3.37) | 2019 | Modelled | IHME |
| 3.04 (2.67 - 3.37) | 2018 | Modelled | IHME |
| 3.04 (2.67 - 3.38) | 2017 | Modelled | IHME |
| 3.04 (2.69 - 3.37) | 2016 | Modelled | IHME |
| 3.06 (2.69 - 3.38) | 2015 | Modelled | IHME |
| 3.07 (2.70 - 3.39) | 2014 | Modelled | IHME |
| 3.08 (2.72 - 3.40) | 2013 | Modelled | IHME |
| 3.09 (2.72 - 3.41) | 2012 | Modelled | IHME |
| 3.1 (2.73 - 3.42) | 2011 | Modelled | IHME |
| 3.11 (2.75 - 3.44) | 2010 | Modelled | IHME |
| 3.13 (2.77 - 3.46) | 2009 | Modelled | IHME |
| 3.15 (2.79 - 3.49) | 2008 | Modelled | IHME |
| 3.18 (2.81 - 3.51) | 2007 | Modelled | IHME |
| 3.2 (2.83 - 3.54) | 2006 | Modelled | IHME |
| 3.21 (2.85 - 3.56) | 2005 | Modelled | IHME |
| 3.22 (2.85 - 3.57) | 2004 | Modelled | IHME |
| 3.23 (2.86 - 3.57) | 2003 | Modelled | IHME |
| 3.23 (2.87 - 3.57) | 2002 | Modelled | IHME |
| 3.24 (2.88 - 3.58) | 2001 | Modelled | IHME |
| 3.24 (2.89 - 3.58) | 2000 | Modelled | IHME |
| 3.26 (2.90 - 3.60) | 1999 | Modelled | IHME |
| 3.27 (2.92 - 3.63) | 1998 | Modelled | IHME |
| 3.29 (2.94 - 3.65) | 1997 | Modelled | IHME |
| 3.3 (2.95 - 3.66) | 1996 | Modelled | IHME |
| 3.31 (2.96 - 3.66) | 1995 | Modelled | IHME |
| 3.31 (2.96 - 3.66) | 1994 | Modelled | IHME |
| 3.3 (2.95 - 3.65) | 1993 | Modelled | IHME |
| 3.3 (2.94 - 3.65) | 1992 | Modelled | IHME |
| 3.29 (2.92 - 3.64) | 1991 | Modelled | IHME |
| 3.28 (2.90 - 3.63) | 1990 | Modelled | IHME |
| 1.97 (1.56 - 2.45) | 2015 | Modelled | WHO |
| 1.02 (1.01 - 1.02) | 2013 | Modelled | Schweitzer et al, 2015 |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.08 (0.06 - 0.10) | 2019 | Modelled | IHME |
| 0.08 (0.07 - 0.11) | 2018 | Modelled | IHME |
| 0.09 (0.07 - 0.11) | 2017 | Modelled | IHME |
| 0.59 (0.47 - 0.74) | 2016 | Modelled | IHME |
| 1.09 (0.87 - 1.37) | 2015 | Modelled | IHME |
| 1.1 (0.88 - 1.38) | 2014 | Modelled | IHME |
| 1.11 (0.88 - 1.39) | 2013 | Modelled | IHME |
| 1.11 (0.89 - 1.39) | 2012 | Modelled | IHME |
| 1.11 (0.89 - 1.40) | 2011 | Modelled | IHME |
| 1.11 (0.89 - 1.40) | 2010 | Modelled | IHME |
| 1.12 (0.89 - 1.41) | 2009 | Modelled | IHME |
| 1.12 (0.89 - 1.41) | 2008 | Modelled | IHME |
| 1.13 (0.89 - 1.42) | 2007 | Modelled | IHME |
| 1.13 (0.89 - 1.42) | 2006 | Modelled | IHME |
| 1.13 (0.89 - 1.42) | 2005 | Modelled | IHME |
| 1.13 (0.89 - 1.42) | 2004 | Modelled | IHME |
| 1.13 (0.89 - 1.42) | 2003 | Modelled | IHME |
| 1.13 (0.89 - 1.42) | 2002 | Modelled | IHME |
| 1.13 (0.89 - 1.43) | 2001 | Modelled | IHME |
| 1.13 (0.89 - 1.43) | 2000 | Modelled | IHME |
| 1.14 (0.90 - 1.43) | 1999 | Modelled | IHME |
| 1.14 (0.91 - 1.44) | 1998 | Modelled | IHME |
| 1.15 (0.92 - 1.45) | 1997 | Modelled | IHME |
| 1.16 (0.92 - 1.47) | 1996 | Modelled | IHME |
| 1.16 (0.93 - 1.47) | 1995 | Modelled | IHME |
| 1.16 (0.93 - 1.46) | 1994 | Modelled | IHME |
| 1.17 (0.93 - 1.47) | 1993 | Modelled | IHME |
| 1.17 (0.93 - 1.46) | 1992 | Modelled | IHME |
| 1.17 (0.93 - 1.47) | 1991 | Modelled | IHME |
| 1.17 (0.93 - 1.47) | 1990 | Modelled | IHME |
| 1.95 (1.50 - 2.53) | 2015 | Modelled | WHO |
| 0.17 | 2010 | Survey/reported | WHO WPRO, Woodring J et al, 2017 |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 5.99 (5.07 - 6.85) | 2019 | Modelled | IHME |
| 5.64 (4.81 - 6.40) | 2018 | Modelled | IHME |
| 5.42 (4.62 - 6.15) | 2017 | Modelled | IHME |
| 5.46 (4.66 - 6.17) | 2016 | Modelled | IHME |
| 5.51 (4.72 - 6.23) | 2015 | Modelled | IHME |
| 5.55 (4.76 - 6.26) | 2014 | Modelled | IHME |
| 5.57 (4.79 - 6.28) | 2013 | Modelled | IHME |
| 5.58 (4.83 - 6.27) | 2012 | Modelled | IHME |
| 5.58 (4.83 - 6.26) | 2011 | Modelled | IHME |
| 5.54 (4.82 - 6.21) | 2010 | Modelled | IHME |
| 5.53 (4.84 - 6.18) | 2009 | Modelled | IHME |
| 5.56 (4.89 - 6.19) | 2008 | Modelled | IHME |
| 5.57 (4.94 - 6.16) | 2007 | Modelled | IHME |
| 5.6 (4.99 - 6.17) | 2006 | Modelled | IHME |
| 5.71 (5.11 - 6.29) | 2005 | Modelled | IHME |
| 5.78 (5.20 - 6.36) | 2004 | Modelled | IHME |
| 5.96 (5.37 - 6.56) | 2003 | Modelled | IHME |
| 6.12 (5.54 - 6.73) | 2002 | Modelled | IHME |
| 6.33 (5.75 - 6.94) | 2001 | Modelled | IHME |
| 6.51 (5.92 - 7.10) | 2000 | Modelled | IHME |
| 6.63 (6.05 - 7.23) | 1999 | Modelled | IHME |
| 6.55 (5.98 - 7.13) | 1998 | Modelled | IHME |
| 6.38 (5.82 - 6.97) | 1997 | Modelled | IHME |
| 6.29 (5.72 - 6.86) | 1996 | Modelled | IHME |
| 6.23 (5.69 - 6.79) | 1995 | Modelled | IHME |
| 5.98 (5.48 - 6.52) | 1994 | Modelled | IHME |
| 5.9 (5.42 - 6.42) | 1993 | Modelled | IHME |
| 5.77 (5.31 - 6.27) | 1992 | Modelled | IHME |
| 5.63 (5.19 - 6.12) | 1991 | Modelled | IHME |
| 5.54 (5.11 - 6.01) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 7,655 (6,475 - 8,750) | 2019 | Modelled | IHME |
| 7,238 (6,162 - 8,203) | 2018 | Modelled | IHME |
| 6,968 (5,940 - 7,908) | 2017 | Modelled | IHME |
| 7,038 (6,006 - 7,954) | 2016 | Modelled | IHME |
| 7,121 (6,101 - 8,054) | 2015 | Modelled | IHME |
| 7,187 (6,166 - 8,105) | 2014 | Modelled | IHME |
| 7,227 (6,214 - 8,142) | 2013 | Modelled | IHME |
| 7,241 (6,271 - 8,145) | 2012 | Modelled | IHME |
| 7,251 (6,279 - 8,138) | 2011 | Modelled | IHME |
| 7,211 (6,265 - 8,082) | 2010 | Modelled | IHME |
| 7,195 (6,297 - 8,035) | 2009 | Modelled | IHME |
| 7,230 (6,363 - 8,047) | 2008 | Modelled | IHME |
| 7,243 (6,425 - 8,008) | 2007 | Modelled | IHME |
| 7,276 (6,484 - 8,010) | 2006 | Modelled | IHME |
| 7,410 (6,640 - 8,164) | 2005 | Modelled | IHME |
| 7,505 (6,750 - 8,255) | 2004 | Modelled | IHME |
| 7,728 (6,967 - 8,498) | 2003 | Modelled | IHME |
| 7,919 (7,168 - 8,719) | 2002 | Modelled | IHME |
| 8,182 (7,428 - 8,970) | 2001 | Modelled | IHME |
| 8,397 (7,633 - 9,160) | 2000 | Modelled | IHME |
| 8,534 (7,795 - 9,309) | 1999 | Modelled | IHME |
| 8,416 (7,682 - 9,170) | 1998 | Modelled | IHME |
| 8,186 (7,471 - 8,935) | 1997 | Modelled | IHME |
| 8,046 (7,322 - 8,777) | 1996 | Modelled | IHME |
| 7,948 (7,265 - 8,663) | 1995 | Modelled | IHME |
| 7,612 (6,976 - 8,301) | 1994 | Modelled | IHME |
| 7,493 (6,887 - 8,155) | 1993 | Modelled | IHME |
| 7,304 (6,728 - 7,943) | 1992 | Modelled | IHME |
| 7,108 (6,556 - 7,724) | 1991 | Modelled | IHME |
| 6,971 (6,436 - 7,565) | 1990 | Modelled | IHME |
| 19,893 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 10 (8 - 12) | 2019 | Modelled | IHME |
| 10 (8 - 11) | 2018 | Modelled | IHME |
| 9 (8 - 11) | 2017 | Modelled | IHME |
| 10 (8 - 11) | 2016 | Modelled | IHME |
| 10 (9 - 12) | 2015 | Modelled | IHME |
| 10 (9 - 12) | 2014 | Modelled | IHME |
| 10 (9 - 12) | 2013 | Modelled | IHME |
| 10 (9 - 12) | 2012 | Modelled | IHME |
| 11 (9 - 12) | 2011 | Modelled | IHME |
| 11 (9 - 12) | 2010 | Modelled | IHME |
| 11 (9 - 13) | 2009 | Modelled | IHME |
| 11 (9 - 13) | 2008 | Modelled | IHME |
| 11 (9 - 13) | 2007 | Modelled | IHME |
| 11 (9 - 13) | 2006 | Modelled | IHME |
| 11 (10 - 13) | 2005 | Modelled | IHME |
| 11 (10 - 13) | 2004 | Modelled | IHME |
| 11 (10 - 13) | 2003 | Modelled | IHME |
| 12 (10 - 14) | 2002 | Modelled | IHME |
| 12 (10 - 14) | 2001 | Modelled | IHME |
| 12 (11 - 14) | 2000 | Modelled | IHME |
| 12 (11 - 14) | 1999 | Modelled | IHME |
| 13 (11 - 15) | 1998 | Modelled | IHME |
| 13 (11 - 15) | 1997 | Modelled | IHME |
| 13 (11 - 15) | 1996 | Modelled | IHME |
| 13 (12 - 15) | 1995 | Modelled | IHME |
| 14 (12 - 16) | 1994 | Modelled | IHME |
| 14 (12 - 16) | 1993 | Modelled | IHME |
| 14 (12 - 16) | 1992 | Modelled | IHME |
| 14 (13 - 17) | 1991 | Modelled | IHME |
| 15 (13 - 17) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HBV testing policy
Universal
HepB birth dose policy
Yes (for risk groups)
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
HCV testing policy
Universal
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.45 (0.29 - 0.63) | 2019 | Modelled | IHME |
| 0.45 (0.29 - 0.63) | 2018 | Modelled | IHME |
| 0.44 (0.28 - 0.62) | 2017 | Modelled | IHME |
| 0.41 (0.28 - 0.57) | 2016 | Modelled | IHME |
| 0.39 (0.27 - 0.53) | 2015 | Modelled | IHME |
| 0.4 (0.27 - 0.54) | 2014 | Modelled | IHME |
| 0.4 (0.28 - 0.54) | 2013 | Modelled | IHME |
| 0.41 (0.29 - 0.54) | 2012 | Modelled | IHME |
| 0.41 (0.30 - 0.54) | 2011 | Modelled | IHME |
| 0.42 (0.31 - 0.54) | 2010 | Modelled | IHME |
| 0.43 (0.32 - 0.55) | 2009 | Modelled | IHME |
| 0.43 (0.33 - 0.55) | 2008 | Modelled | IHME |
| 0.44 (0.34 - 0.56) | 2007 | Modelled | IHME |
| 0.46 (0.35 - 0.58) | 2006 | Modelled | IHME |
| 0.47 (0.37 - 0.59) | 2005 | Modelled | IHME |
| 0.52 (0.41 - 0.64) | 2004 | Modelled | IHME |
| 0.6 (0.48 - 0.75) | 2003 | Modelled | IHME |
| 0.69 (0.55 - 0.86) | 2002 | Modelled | IHME |
| 0.77 (0.61 - 0.96) | 2001 | Modelled | IHME |
| 0.8 (0.63 - 1) | 2000 | Modelled | IHME |
| 0.79 (0.62 - 0.98) | 1999 | Modelled | IHME |
| 0.77 (0.61 - 0.96) | 1998 | Modelled | IHME |
| 0.75 (0.59 - 0.92) | 1997 | Modelled | IHME |
| 0.72 (0.57 - 0.89) | 1996 | Modelled | IHME |
| 0.7 (0.56 - 0.87) | 1995 | Modelled | IHME |
| 0.69 (0.55 - 0.85) | 1994 | Modelled | IHME |
| 0.69 (0.55 - 0.84) | 1993 | Modelled | IHME |
| 0.68 (0.54 - 0.84) | 1992 | Modelled | IHME |
| 0.67 (0.53 - 0.83) | 1991 | Modelled | IHME |
| 0.67 (0.53 - 0.83) | 1990 | Modelled | IHME |
| 0.7 (0.30 - 0.80) | 2015 | Modelled | Blach et al, 2017 |
| 1.1 (0.40 - 1.70) | 2014 | Modelled | Gower et al, 2014 |
Showing out of
Show more
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.5 (0.50 - 2.20) | 2014 | Modelled | Gower et al, 2014 |
| 1.5 (0.50 - 2.20) | 2014 | Modelled | Gower et al, 2014 |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 64.8 (55 - 74.50) | 1994 | Modelled | Nelson P et al, 2011 |
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 29.6 (24.90 - 32.40) | 2019 | Modelled | IHME |
| 29.3 (24.50 - 31.90) | 2018 | Modelled | IHME |
| 28.6 (24 - 31.20) | 2017 | Modelled | IHME |
| 28.4 (23.80 - 31) | 2016 | Modelled | IHME |
| 28.2 (23.60 - 30.60) | 2015 | Modelled | IHME |
| 28.3 (23.90 - 30.80) | 2014 | Modelled | IHME |
| 28.6 (24.30 - 31.10) | 2013 | Modelled | IHME |
| 28.9 (24.70 - 31.40) | 2012 | Modelled | IHME |
| 29.2 (25.10 - 31.70) | 2011 | Modelled | IHME |
| 29.2 (25.30 - 31.50) | 2010 | Modelled | IHME |
| 29.3 (25.50 - 31.40) | 2009 | Modelled | IHME |
| 29.7 (26.20 - 31.80) | 2008 | Modelled | IHME |
| 29.9 (26.60 - 32) | 2007 | Modelled | IHME |
| 30 (26.90 - 32) | 2006 | Modelled | IHME |
| 30.2 (27.20 - 32.10) | 2005 | Modelled | IHME |
| 29.8 (27.10 - 31.60) | 2004 | Modelled | IHME |
| 29.6 (26.90 - 31.20) | 2003 | Modelled | IHME |
| 29 (26.60 - 30.60) | 2002 | Modelled | IHME |
| 28.9 (26.60 - 30.40) | 2001 | Modelled | IHME |
| 28.9 (26.70 - 30.40) | 2000 | Modelled | IHME |
| 28.9 (26.80 - 30.40) | 1999 | Modelled | IHME |
| 28.2 (26.20 - 29.60) | 1998 | Modelled | IHME |
| 27 (25.30 - 28.40) | 1997 | Modelled | IHME |
| 26.2 (24.60 - 27.60) | 1996 | Modelled | IHME |
| 25.4 (23.90 - 26.60) | 1995 | Modelled | IHME |
| 23.8 (22.40 - 25) | 1994 | Modelled | IHME |
| 23 (21.70 - 24.10) | 1993 | Modelled | IHME |
| 22 (20.70 - 23) | 1992 | Modelled | IHME |
| 21 (19.80 - 22) | 1991 | Modelled | IHME |
| 20.2 (19.10 - 21.20) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 37,843 (31,786 - 41,392) | 2019 | Modelled | IHME |
| 37,558 (31,422 - 40,944) | 2018 | Modelled | IHME |
| 36,807 (30,885 - 40,097) | 2017 | Modelled | IHME |
| 36,581 (30,748 - 39,942) | 2016 | Modelled | IHME |
| 36,383 (30,467 - 39,590) | 2015 | Modelled | IHME |
| 36,644 (30,911 - 39,935) | 2014 | Modelled | IHME |
| 37,108 (31,489 - 40,371) | 2013 | Modelled | IHME |
| 37,549 (32,035 - 40,774) | 2012 | Modelled | IHME |
| 37,965 (32,603 - 41,156) | 2011 | Modelled | IHME |
| 37,992 (32,893 - 40,985) | 2010 | Modelled | IHME |
| 38,077 (33,159 - 40,895) | 2009 | Modelled | IHME |
| 38,590 (34,014 - 41,380) | 2008 | Modelled | IHME |
| 38,899 (34,565 - 41,571) | 2007 | Modelled | IHME |
| 39,037 (35,011 - 41,543) | 2006 | Modelled | IHME |
| 39,208 (35,360 - 41,632) | 2005 | Modelled | IHME |
| 38,711 (35,207 - 40,978) | 2004 | Modelled | IHME |
| 38,311 (34,854 - 40,490) | 2003 | Modelled | IHME |
| 37,600 (34,415 - 39,657) | 2002 | Modelled | IHME |
| 37,343 (34,374 - 39,314) | 2001 | Modelled | IHME |
| 37,295 (34,463 - 39,200) | 2000 | Modelled | IHME |
| 37,226 (34,468 - 39,161) | 1999 | Modelled | IHME |
| 36,186 (33,732 - 38,036) | 1998 | Modelled | IHME |
| 34,656 (32,481 - 36,417) | 1997 | Modelled | IHME |
| 33,494 (31,492 - 35,269) | 1996 | Modelled | IHME |
| 32,402 (30,463 - 34,004) | 1995 | Modelled | IHME |
| 30,336 (28,548 - 31,824) | 1994 | Modelled | IHME |
| 29,183 (27,521 - 30,634) | 1993 | Modelled | IHME |
| 27,818 (26,212 - 29,165) | 1992 | Modelled | IHME |
| 26,461 (24,941 - 27,753) | 1991 | Modelled | IHME |
| 25,401 (23,982 - 26,667) | 1990 | Modelled | IHME |
| 18,195 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 73 (69 - 75) | 2019 | Modelled | IHME |
| 73 (70 - 76) | 2018 | Modelled | IHME |
| 73 (70 - 76) | 2017 | Modelled | IHME |
| 73 (70 - 75) | 2016 | Modelled | IHME |
| 72 (69 - 75) | 2015 | Modelled | IHME |
| 72 (69 - 75) | 2014 | Modelled | IHME |
| 72 (69 - 75) | 2013 | Modelled | IHME |
| 72 (68 - 74) | 2012 | Modelled | IHME |
| 71 (68 - 74) | 2011 | Modelled | IHME |
| 71 (68 - 74) | 2010 | Modelled | IHME |
| 71 (68 - 74) | 2009 | Modelled | IHME |
| 71 (68 - 74) | 2008 | Modelled | IHME |
| 71 (68 - 74) | 2007 | Modelled | IHME |
| 71 (68 - 73) | 2006 | Modelled | IHME |
| 71 (68 - 73) | 2005 | Modelled | IHME |
| 70 (67 - 73) | 2004 | Modelled | IHME |
| 70 (67 - 73) | 2003 | Modelled | IHME |
| 70 (67 - 72) | 2002 | Modelled | IHME |
| 69 (66 - 72) | 2001 | Modelled | IHME |
| 69 (66 - 72) | 2000 | Modelled | IHME |
| 69 (66 - 71) | 1999 | Modelled | IHME |
| 68 (65 - 71) | 1998 | Modelled | IHME |
| 68 (65 - 71) | 1997 | Modelled | IHME |
| 68 (65 - 71) | 1996 | Modelled | IHME |
| 67 (64 - 70) | 1995 | Modelled | IHME |
| 67 (64 - 70) | 1994 | Modelled | IHME |
| 67 (64 - 70) | 1993 | Modelled | IHME |
| 66 (63 - 69) | 1992 | Modelled | IHME |
| 66 (63 - 69) | 1991 | Modelled | IHME |
| 65 (62 - 68) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 300 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HBV testing policy
Universal
HepB birth dose policy
Yes (for risk groups)
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
HCV testing policy
Universal
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
HBV (HBsAg+)
3.04
(%)
2019
(2.67 - 3.37(%))
IHME
HCV (RNA/cAg+)
0.45
(%)
2019
(0.29 - 0.63(%))
IHME
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
7,655
2019
(6,475 - 8,750)
IHME
Survey/surveillance
No data available
HBV chart
Modelled
HCV
37,843
2019
(31,786 - 41,392)
IHME
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.17
(%)
2010, survey/surveillance
WHO WPRO, Woodring J et al, 2017
Prevalence PWID
HCV
64.80
(%)
1994, latest modelled
(55 - 74.50(%))
Nelson P et al, 2011
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines